BioPharmSignal logoBioPharmSignal

Biotech News

Dyne Therapeutics Announces Upcoming Presentation Highlighting Robust CNS Activity in Nonhuman Primates with its FORCE™ Platform at 2026 ASGCT Annual Meeting

Dyne Therapeutics (DYN)Dyne TherapeuticsConference / presentation

- Data underscore the differentiated capability of the clinically validated FORCE platform to cross the blood-brain barrier - WALTHAM, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people

Related news

DYNDyne Therapeutics2026-02-22 21:00 EST

Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference

DYNDyne Therapeutics2026-04-01 11:30 EST

Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines

View all latest news

Dyne Therapeutics

Oligonucleotide Therapeutics Dyne Therapeutics develops targeted oligonucleotide medicines for genetically driven muscle diseases. Its FORCE platform links therapeutic payloads to antibodies intended to improve delivery into muscle tissue. Duchenne Muscular Dystrophy Z-rostudirsen is designed for patients with Duchenne muscular dystrophy...

Recent company news

DYNDyne Therapeutics2026-08-20 20:05 EST

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYNDyne Therapeutics2026-07-29 20:30 EST

Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

DYNDyne Therapeutics2026-07-28 11:30 EST

Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)

DYNDyne Therapeutics2026-07-24 20:05 EST

Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

DYNDyne Therapeutics2026-07-23 20:05 EST

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Stock data

Close
26.10 USD
Market cap
2.85B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States